ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
N-sulfonylated indole hydrazone hybrid targeting Staphylococcus aureus with compelling antibiofilm and membrane-disrupting properties.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Staphylococcus aureus is a highly adaptable opportunistic pathogen and a leading cause of infectious disease-related morbidity and mortality globally. This pathogen triggers a wide spectrum of infections, from mild skin infections to life-threatening conditions like sepsis and pneumonia. Thus, it is implicated in escalating the global antimicrobial resistance (AMR) crisis, and there is an urgent need for novel antistaphylococcal scaffolds. In response to this challenge, we previously reported a metal-free electrochemical strategy for regioselective synthesis of N-sulfonylated indole-based hydrazone derivatives, identifying compound 5d as a potent lead with an MIC of 6.87 µM against the S. aureus pathogen. Building upon this, our current study provides a comprehensive antibacterial and mechanistic evaluation of the 5d molecule against the S. aureus pathogen. The antibacterial susceptibility analyses, including time-kill kinetics and anti-biofilm assays, demonstrated significant inhibitory effects. Further, mechanistic investigations revealed that potent hit (5d) triggers a multi-targeted bactericidal action. It compromised bacterial membrane integrity, resulting in leakage of cell contents, increased membrane permeability, and heightened oxidative stress through ROS generation. Next, the ATP quantification study revealed that the compound interferes with bacterial cellular bioenergetics by depleting the intracellular ATP levels. These findings highlight the compound 5d as a promising scaffold against S. aureus infections and successfully establish the sulfonylated-indole hydrazones as capable pharmacophores for next-generational antibacterial drug discovery efforts to mitigate the global AMR burden.
Indexed as
Identifiers
42429828What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.